We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 88.42% |
| 2 | Financials | 1.51% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCIIU
126
Cohen Circle Acquisition Corp II Unit
CCIIU
$272M
| $1.55M | 0.09% |
150,000
| – | – |
|
127
Rocket Pharmaceuticals
RCKT
$372M
| $1.55M | 0.09% |
432,500
-43,300
| -9% | -$172K |
|
128
Supernus Pharmaceuticals
SUPN
$2.8B
| $1.53M | 0.09% |
29,642
-100
| -0.3% | -$5.09K |
|
|
CNTA
129
DELISTED
Centessa Pharmaceuticals
CNTA
| $1.53M | 0.09% |
38,566
| – | – |
|
|
FOLD
130
DELISTED
Amicus Therapeutics
FOLD
| $1.52M | 0.09% |
+105,000
| New | +$1.51M |
|
|
MAZE
131
Maze Therapeutics
MAZE
$1.5B
| $1.5M | 0.09% |
50,095
-129,437
| -72% | -$5.71M |
|
132
UnitedHealth
UNH
$384B
| $1.49M | 0.09% |
+5,501
| New | +$1.64M |
|
|
ADGM
133
Adagio Medical Holdings
ADGM
$11.8M
| $1.39M | 0.08% |
1,205,447
+45,833
| +4% | +$46.5K |
|
134
Forward Air
FWRD
$429M
| $1.31M | 0.08% |
78,241
+51,606
| +194% | +$1.26M |
|
135
Sensient Technologies
SXT
$4.72B
| $1.3M | 0.08% |
+15,000
| New | +$1.4M |
|
136
Kiniksa Pharmaceuticals
KNSA
$4.7B
| $1.3M | 0.08% |
26,913
-1,815
| -6% | -$80.4K |
|
137
Corvus Pharmaceuticals
CRVS
$1.2B
| $1.29M | 0.08% |
87,901
-377,974
| -81% | -$6.03M |
|
|
MSLE
138
Satellos Bioscience
MSLE
$182M
| $1.25M | 0.07% |
+222,555
| New | +$2.19M |
|
139
uniQure
QURE
$2.71B
| $1.25M | 0.07% |
76,206
-158,949
| -68% | -$3.22M |
|
|
NVO
140
Novo Nordisk
NVO
$228B
| $1.21M | 0.07% |
+33,000
| New | +$1.56M |
|
141
ProMIS Neurosciences
PMN
$119M
| $1.21M | 0.07% |
+95,350
| New | +$1.42M |
|
142
Lexicon Pharmaceuticals
LXRX
$995M
| $1.17M | 0.07% |
+750,000
| New | +$1.09M |
|
143
Schrodinger
SDGR
$1.17B
| $1.15M | 0.07% |
+101,500
| New | +$1.4M |
|
144
CALL
Karyopharm Therapeutics
KPTI
$213M
| $1.14M | 0.07% |
+205,200
| New | +$1.56M |
|
145
Xencor
XNCR
$1.11B
| $1.13M | 0.07% |
93,665
+37,500
| +67% | +$465K |
|
146
OmniAb
OABI
$296M
| $1.11M | 0.07% |
705,190
+3,000
| +0.4% | +$5.41K |
|
147
4D Molecular Therapeutics
FDMT
$567M
| $1.09M | 0.06% |
116,712
| – | – |
|
148
Keros Therapeutics
KROS
$210M
| $1.07M | 0.06% |
97,318
+78,467
| +416% | +$1.21M |
|
|
DAWN
149
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.07M | 0.06% |
+49,923
| New | +$703K |
|
150
Bristol-Myers Squibb
BMY
$124B
| $1.06M | 0.06% |
17,500
-2,500
| -13% | -$146K |
|
Similar funds
RSCM
AAM
SGI
WAS
BCM
SWM
TCM
ISS